Quantum-Si (NASDAQ:QSI) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Quantum-Si reported a quarterly loss of $0.10 per share, beating estimates of a $0.12 loss, but revenue of $212,000 missed the $270,000 forecast and fell from $552,000 a year earlier.
• Its Proteus instrument remains on track for a second-quarter 2027 launch. The company reported encouraging interim performance and is pursuing pre-orders, but did not disclose order numbers.
• Quantum-Si reiterated 2026 revenue guidance of about $1 million while lowering its adjusted operating expense and cash-use outlook to $87 million or less each. It reported $149.4 million in cash and expects funding to last into the fourth quarter of 2028.

Quantum-Si (NASDAQ:QSI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02, FiscalAI reports. The company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.27 million. Quantum-Si had a negative return on equity of 47.12% and a negative net margin of 6,138.26%.

Here are the key takeaways from Quantum-Si's conference call:

• Quantum-Si said Proteus remains on track for a second-quarter 2027 launch. It reported that instrument design is complete, variability issues are substantially addressed, and manufacturing of the next development build is underway, with initial instruments expected this quarter.
• The company has demonstrated detection of 19 amino acids and expects to demonstrate the 20th by year-end, with all 20 targeted for launch. At World HUPO, interim Proteus results showed about 30 times more sequencing output per chamber than Platinum Pro and a lower false discovery rate, though management said the product is still in development.
• Quantum-Si has held Proteus Roadshow events in more than 35 cities and launched a pre-order program offering priority access and pricing. Management described prospective-customer interest as encouraging and said the sales funnel includes both existing users and new accounts, but did not disclose order numbers.
• Revenue fell to $212,000 from $552,000 year over year in the quarter, and the company reiterated full-year 2026 revenue guidance of about $1 million as customers await Proteus. Quantum-Si reported $149.4 million in cash, equivalents and marketable securities and said it expects funding to last into the fourth quarter of 2028.
• The company lowered its 2026 adjusted operating expense outlook to $87 million or less from $98 million or less and cash-use outlook to $87 million or less from $93 million or less, citing cost actions and discipline. It is also ordering long-lead components earlier amid AI-related supply constraints, which may increase near-term working capital needs; management said it does not currently expect the constraints to affect the launch timeline.

Quantum-Si Stock Up 13.7%

NASDAQ:QSI traded up $0.16 on Friday, reaching $1.33. 8,206,582 shares of the stock traded hands, compared to its average volume of 9,981,961. Quantum-Si has a 12 month low of $0.69 and a 12 month high of $1.81. The company's fifty day simple moving average is $1.08 and its 200 day simple moving average is $0.97.

Analyst Upgrades and Downgrades

Several research firms recently commented on QSI. Weiss Ratings raised shares of Quantum-Si from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 24th. Alliance Global Partners reiterated a "buy" rating on shares of Quantum-Si in a report on Friday, August 14th. HC Wainwright set a $4.00 price target on Quantum-Si in a research report on Friday, October 9th. Finally, Wall Street Zen raised Quantum-Si from a "sell" rating to a "hold" rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $2.50.

About Quantum-Si

Quantum-Si Incorporated NASDAQ: QSI is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine.

Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.